Related by context. All words. (Click for frequent words.) 75 prostate cancer CaP 75 urothelial carcinoma 75 mucinous 75 prostate carcinoma 74 pancreatic adenocarcinoma 74 thyroid carcinoma 73 pulmonary metastases 73 breast carcinomas 73 epithelial ovarian cancer 72 lobular carcinoma 72 leiomyomas 72 epithelial ovarian 72 LHRH receptor positive 72 papillary renal cell carcinoma 72 sarcomatoid 72 nodal metastasis 71 distant metastasis 71 atypical hyperplasia 71 HNSCC 71 ductal carcinomas 71 GISTs 71 colorectal carcinoma 71 distant metastases 71 situ LCIS 71 epithelial tumors 71 renal carcinoma 71 operable breast cancer 71 invasive ductal 71 endometrial cancers 71 lymphocytosis 71 HGPIN 71 immunohistochemical staining 70 lymph node metastases 70 carcinoid tumor 70 ovarian carcinoma 70 squamous cell carcinoma SCC 70 nonmetastatic 70 PCa 70 cervical lymph nodes 70 seminoma 70 invasive carcinoma 70 gastric carcinoma 70 neoplasms 70 node metastases 70 Endometrial 70 lymph node metastasis 70 nodal metastases 70 cisplatin resistant 70 gastric adenocarcinoma 70 adenocarcinomas 70 pCR 70 adenomatous 70 axillary lymph nodes 70 pT2 70 pheochromocytoma 70 Papillary 69 cervical carcinoma 69 NMIBC 69 Lymph node 69 leiomyoma 69 histological subtype 69 basal cell carcinoma BCC 69 histologic subtype 69 endometrial carcinoma 69 liver metastasis 69 pathologic diagnosis 69 CIN2 + 69 renal tumors 69 paragangliomas 69 CIN3 69 prognostic significance 69 normal karyotype 69 hamartomas 69 renal cell carcinomas 69 colorectal adenoma 69 osteosarcomas 69 locoregional recurrence 69 precursor lesions 69 endometrial hyperplasia 69 histologically 69 bladder carcinoma 69 neoplasm 69 tumorigenicity 69 BRCA mutation carriers 69 tumoral 69 immunohistochemical analysis 69 neoplastic 69 F FDG PET 69 invasive lobular carcinoma 69 estrogen receptor ER 69 hyperplastic 68 HER2 overexpression 68 ASCUS 68 urothelial cancer 68 KRAS mutations 68 serous ovarian cancer 68 BRCA2 mutation carriers 68 lymphadenectomy 68 neoplastic cells 68 lymphadenopathy 68 micrometastases 68 hamartoma 68 immunohistochemical 68 pelvic lymphadenectomy 68 hepatocellular carcinomas 68 micrometastasis 68 intestinal metaplasia 68 HER2 positive cancers 68 adenoma 68 carcinoma 68 hepatoma 68 contralateral breast 68 esophageal carcinoma 68 histopathologic examination 68 differentiated thyroid 68 urolithiasis 68 malignant lymphoma 68 TOP2A 68 metastatic malignant 68 surgically resected 68 mutated K ras 68 biochemical recurrence 68 xenograft tumors 68 lobular cancer 68 metaplasia 68 lymphomas leukemias 68 cytologic 68 localized renal 68 recurrent ovarian 68 fallopian tube carcinoma 68 HER2 amplification 68 thyroid nodules 68 neoplastic lesions 68 HER2 expression 68 neoadjuvant therapy 68 bladder tumors 68 endometrial 68 neoplasia 68 urothelial 67 MALT lymphoma 67 HepG2 cells 67 prostate cancer PCa 67 prostate adenocarcinoma 67 K ras mutations 67 tumor histology 67 ERBB2 67 papillary carcinoma 67 squamous cell lung cancer 67 ERalpha 67 metastatic lesions 67 chemoradiotherapy 67 hepatic metastases 67 salpingo oophorectomy 67 atypia 67 haematopoietic 67 carcinoid 67 papillary thyroid carcinoma 67 invasive lobular 67 metastatic neuroendocrine tumors 67 TIMP 67 lymphovascular invasion 67 ADPKD 67 metachronous 67 fibroma 67 tumor recurrence 67 metastatic lesion 67 mediastinal 67 endometrioid 67 ErbB2 positive 67 histologic 67 mRNA expression 67 biliary tract cancer 67 BRCA1 mutation carriers 67 thyroglobulin 67 underwent resection 67 urine cytology 67 radical nephrectomy 67 Hurthle cell 67 malignant prostate 67 pancreatic lung 67 VEGF expression 67 pT3 67 taxane resistant 67 transitional cell carcinoma 66 orthotopic 66 locoregional 66 paraganglioma 66 histologic examination 66 axillary nodes 66 premalignant 66 pleomorphic 66 cytoreduction 66 supratentorial 66 adenomatous polyps 66 lymphocytic 66 Clusterin 66 clinicopathological features 66 ABCB1 66 nasopharyngeal carcinoma 66 #F FDG PET 66 hyperplasia 66 pituitary adenomas 66 leukemia AML 66 ductal breast cancer 66 advanced adenomas 66 polyposis 66 colorectal neoplasms 66 colorectal adenocarcinoma 66 nonsmall cell lung cancer 66 SLNB 66 cervical intraepithelial neoplasia 66 castrate resistant 66 adjuvant radiotherapy 66 esophagogastric junction 66 colorectal gastric 66 MDA MB 66 chlamydial infection 66 cutaneous squamous cell carcinoma 66 cystectomy 66 papillary 66 Immunohistochemical staining 66 advanced adenoma 66 tumor subtypes 66 metastatic prostate 66 ductal 66 progesterone receptor negative 66 hormone receptor status 66 immunostaining 66 malignant lesions 66 underwent surgical resection 66 axillary dissection 66 chemoresistant 66 thymoma 66 bone metastasis 66 lobular carcinomas 66 histopathological 66 GSTP1 66 subependymal giant cell 66 extracapsular extension 66 T1DM 66 axillary lymph node 66 testicular germ cell 66 T1a 66 carcinoid tumors 66 invasive carcinomas 66 radiosensitivity 66 seminomas 66 ductal cancer 66 T1c 66 peritoneal carcinomatosis 66 nonmelanoma skin cancers 66 invasive ductal carcinoma 66 lymph node involvement 66 TMPRSS2 ERG 66 prognostic biomarker 66 BRCA deficient 66 abnormal cytology 65 nonalcoholic steatohepatitis NASH 65 liver metastases 65 grade cervical intraepithelial 65 neoplasias 65 cutaneous melanoma 65 urothelial bladder cancer 65 gastrointestinal stromal tumors GISTs 65 neoadjuvant chemotherapy 65 hypermethylated 65 specific antigen PSA 65 malignant pleural mesothelioma 65 Squamous 65 lobular breast cancer 65 breast cancer subtypes 65 CLL SLL 65 missense mutations 65 PSADT 65 pathologic examination 65 Immunohistochemical analysis 65 cyclin E 65 malignant ovarian 65 atypical ductal hyperplasia 65 pulmonary metastasis 65 ductal adenocarcinoma 65 metastatic lymph nodes 65 papillomas 65 Sjögren syndrome 65 cytokeratin 65 metastatic renal cell carcinoma 65 GIST tumors 65 histologically confirmed 65 skeletal metastases 65 gastric cardia 65 IgA deficiency 65 debulking surgery 65 cytological 65 recurrent glioblastoma multiforme 65 fallopian tube cancers 65 LHRH agonists 65 carcinomas 65 activating mutations 65 germline mutations 65 hypervascular 65 testicular cancers 65 metastases 65 ependymoma 65 WT1 65 nodal dissection 65 cervical lymph node 65 clinicopathologic 65 taxane therapy 65 oesophageal adenocarcinoma 65 MGUS 65 Adjuvant chemotherapy 65 immunocompetent 65 TOP2A gene 65 lymph node dissection 65 stage IIIB 65 sonographic findings 65 androgen deprivation 65 cholangiocarcinoma 65 osteoid 65 histologic findings 65 metastatic gastric 65 histopathologic findings 65 Estrogen Receptor 65 biochemical relapse 65 ductal lobular 65 GBM tumors 65 colorectal carcinomas 65 colonic polyps 65 prostate carcinomas 65 gadolinium enhanced 65 thyrotoxicosis 65 HER2 positive tumors 65 trans retinoic acid 65 Ductal carcinoma 65 HER2 positive metastatic breast 65 HBeAg negative 65 histologic subtypes 65 BRAF V#E mutation 65 duplex ultrasonography 65 colorectal tumor 65 peritoneal cancer 65 DCIS ductal carcinoma 65 advanced neoplasia 65 hematopoietic cancers 65 ultrasonographic 65 node metastasis 65 histologically proven 65 CIN2 65 hydronephrosis 65 retroperitoneal 65 radiographic findings 65 pretransplant 65 leukocytosis 65 pericardial effusion 65 preoperative chemotherapy 65 Response Evaluation Criteria 65 Carcinoma 65 myxoid 65 chromosomal aberrations 65 CC genotype 65 curative resection 65 IGF IR 65 BRCA1 BRCA2 65 mesenteric 65 colorectal cancer CRC 64 choriocarcinoma 64 wedge resection 64 EGFR gene 64 fibroadenomas 64 response pCR 64 CDH1 64 adrenalectomy 64 transgene expression 64 lung carcinomas 64 intestinal polyps 64 xenograft models 64 morphologic 64 gastrointestinal stromal tumor GIST 64 telomere lengths 64 esophageal gastric 64 endocrine therapies 64 situ CIS 64 precancerous cervical 64 thymectomy 64 neovascular 64 colorectal liver metastases 64 syngeneic 64 radioiodine therapy 64 neoadjuvant 64 recurrent metastatic 64 microvessel density 64 lymphangiogenesis 64 pancreatic islet cell 64 progesterone receptor PR 64 malignant neoplasm 64 superficial bladder cancer 64 myeloproliferative diseases 64 hormone receptor negative 64 extramedullary 64 xenografts 64 serum prostate 64 BRAF V#E 64 androgen ablation 64 hypogonadotropic hypogonadism 64 PCNSL 64 clinically localized prostate 64 miR #a [001] 64 calculi 64 sentinel lymph node biopsy 64 breast endometrial 64 NSCLC tumors 64 lung adenocarcinomas 64 ALND 64 Leydig cell 64 Prognostic factors 64 cervical lesions 64 Adenomas 64 KRAS mutation 64 malignant nodules 64 radiochemotherapy 64 relapsed ovarian cancer 64 SSc 64 appendiceal 64 SUVmax 64 Histologic 64 lung metastasis 64 Radical prostatectomy 64 immunoreactivity 64 mesotheliomas 64 relapsed MM 64 choroidal neovascularization 64 IV NSCLC 64 clinicopathological 64 HER2 gene 64 cellularity 64 Metastases 64 pathologic 64 Epidermal Growth Factor Receptor 64 vascular lesion 64 thromboembolic disease 64 ipsilateral breast 64 microsatellite instability 64 orchiectomy 64 EGFR mutations 64 mammographic density 64 leukaemias 64 hyperparathyroidism 64 Cytogenetic 64 baseline LDH 64 lung metastases 64 diabetes mellitus DM 64 murine model 64 HER2 negative 64 Anthracycline 64 mycosis fungoides 64 Gleevec resistant 64 Histologically 64 astrocytoma 64 transabdominal 64 nephrectomy 64 mammary tumors 64 haematological 64 Acute Myeloid Leukaemia AML 64 Leukemias 64 rectal carcinoma 64 radiotherapy RT 64 inducible nitric oxide synthase 64 myeloperoxidase 64 scintigraphic 64 cytoreductive surgery 64 histological subtypes 64 Hepatocellular Carcinoma HCC 64 epithelioid 64 malignant neoplasms 64 neuroblastoma tumors 64 promoter methylation 64 adjuvant cisplatin 64 primary hyperparathyroidism 64 intact parathyroid hormone 64 atrophic gastritis 64 FDG PET 64 CaP 64 homozygotes 64 hemodilution 64 RRM1 64 elevated LDH 64 histopathologic 64 infiltrating ductal carcinoma 64 kidney cysts 64 transurethral resection 64 hepatocellular carcinoma HCC 64 chest radiographs 64 FDG PET imaging 64 infarcts 64 Metastatic 64 bone scintigraphy 64 pancreatic carcinoma 64 Doxil ® 64 alkaline phosphatase ALP 64 premalignant lesions 64 leukoencephalopathy 64 CEACAM1 64 gene polymorphism 64 extracranial 64 gene amplification 63 thyrotropin 63 hormone receptor positive 63 B7 H3 63 Glioblastoma Multiforme GBM 63 FDG-PET/CT 63 haematologic 63 clinico pathological 63 FGFR4 63 PNET 63 FGFR2 63 lymphoproliferative disorders 63 recurrent NSCLC 63 PAOD 63 metastatic bladder 63 KRAS status 63 unresectable tumors 63 splenic 63 radical prostatectomy RP 63 percutaneous biopsy 63 Mitomycin C 63 pheochromocytomas 63 AGTR1 63 cranial irradiation 63 contralateral breast cancer 63 HER2 positivity 63 transfusion syndrome 63 uterine cervix 63 interferon IFN 63 malignant ascites 63 #F FDG 63 KRAS mutations occur 63 metastatic colorectal 63 fine needle aspiration 63 completely resected 63 ependymomas 63 FDG uptake 63 anterior uveitis 63 metastatic malignant melanoma 63 mRCC 63 carcinoembryonic antigen 63 Bezielle 63 histological diagnosis 63 vestibular schwannomas 63 stage IIIA 63 BRAF mutation 63 receptor tyrosine kinase inhibitor 63 Anaplastic 63 Subgroup analysis 63 estrogen receptor negative 63 stage IIIb IV 63 perineural invasion 63 seropositivity 63 perioperative complications 63 lipomas 63 total thyroidectomy 63 LNCaP cells 63 desmoplastic 63 liver transplant recipients 63 bladder cancers 63 bronchogenic carcinoma 63 seminal vesicle invasion 63 somatic mutations 63 Malignant Melanoma 63 uveal melanoma 63 SPINK1 63 prognostic indicator 63 Polymorphisms 63 coinfected patients 63 granulomatous 63 testicular tumors 63 anaplastic 63 IDH1 mutation 63 HRCT 63 polypoid 63 B Cell Lymphoma 63 adrenocortical 63 hepatorenal syndrome 63 cell carcinomas 63 tumor regressions 63 FGFR2 gene 63 hyperalgesia 63 androgen receptor AR 63 malignant lymphomas 63 surgically resectable 63 ovarian carcinomas 63 diagnostic biomarker 63 antiangiogenic therapy 63 univariate analysis 63 K ras 63 Adenocarcinoma 63 luminal 63 tumor xenografts 63 acute myeloid 63 bladder ovarian 63 seronegative 63 ovarian lung 63 osteoid osteoma 63 Acute myeloid leukemia 63 lymph node removal 63 chemoradiation therapy 63 cholelithiasis 63 EUS FNA 63 metastatic RCC 63 resected pancreatic cancer 63 microdeletions 63 coronary stenosis 63 cytoreductive nephrectomy 63 HBeAg 63 renal pelvis 63 RECIST Response Evaluation Criteria 63 Glioma 63 malignant fibrous histiocytoma 63 GnRH agonist 63 multivariate analyzes 63 multicentric 63 androgen dependent 63 renal cysts 63 mTOR inhibitors 63 sonographic appearance 63 carotid stenosis 63 demyelinating 63 gefitinib Iressa 63 Heavy menstrual bleeding 63 Glioblastoma Multiforme 63 prognostic factor 63 idiopathic myelofibrosis 63 chromosomal rearrangement 63 sonographically guided 63 breast lesions 63 axillary node 63 oophorectomy 63 resectable 63 squamous cell cancers 63 tumors GIST 63 IL 1ß 63 MLH1 63 karyotypes 63 HER2 neu 63 SLN biopsy 63 prognostic variables 63 hepatocellular cancer 63 nephron sparing surgery 63 bilateral oophorectomy 63 taxane chemotherapy 63 EGFR mutant 63 carotid plaques 63 prognostic marker 63 antiproliferative effects 63 fibrin deposition 63 sonographically 63 Adjuvant therapy 63 ^ sup #m 63 mCRC patients 63 gastric cancer 63 alkylating agent 63 EGFR mutation 63 trastuzumab Herceptin ® 63 rs# [004] 63 nondiabetic patients 63 schwannomas 63 malignant pancreatic 63 prostate cancer CRPC 63 KRAS wild 63 colorectal tumors 63 adverse cytogenetics 63 ALT flares 63 cystoscopic 63 cystic lesions 63 colon rectal 63 systolic dysfunction 63 carcinoids 63 fibrocystic 63 colorectal polyp 63 transthyretin amyloidosis 63 pituitary hormones 63 TACE 63 pancreatectomy 63 postoperative radiotherapy 63 cytogenic 63 pDC 63 metastatic cancer 63 mesangial 63 pre cancerous lesion 63 intrahepatic 63 COX2 63 surgical excision 63 meningiomas 62 orchitis 62 HIV HCV coinfected 62 neointimal 62 CP CPPS 62 hepatocellular carcinoma 62 neuroendocrine carcinoma 62 prophylactic cranial irradiation 62 duodenal 62 Histological 62 chromophobe 62 flutamide 62 basal cell nevus syndrome 62 eosinophil count 62 EBRT 62 hepatic cirrhosis 62 sentinel lymph nodes 62 astrocytomas 62 biopsy specimens 62 cell carcinoma 62 CD# expression [001] 62 P cadherin 62 hypereosinophilic syndrome 62 histological examination 62 eccrine 62 neoadjuvant chemoradiotherapy 62 imatinib therapy 62 colorectum 62 explants 62 TT genotype 62 GnRH agonists 62 proximal colon 62 demonstrated antitumor activity 62 benign neoplasms 62 beta1 integrin 62 malignant growths 62 sonographic evaluation 62 neovascularization 62 neurofibromas 62 lobular 62 primary peritoneal 62 prognostic factors 62 PDGFRA 62 CMV infection 62 polycystic ovary syndrome PCOS 62 hypervascular tumors 62 colon carcinoma 62 HER2/neu 62 thrombophilia 62 LRP5 62 lactate dehydrogenase LDH 62 KRAS oncogene 62 macroalbuminuria 62 ultrastructural 62 radical retropubic prostatectomy 62 p# mutation 62 decompensated cirrhosis 62 neuroblastomas 62 mL/min/#.# m 2 62 core needle biopsy 62 COL#A# 62 GH deficiency 62 cardiac troponin T 62 HCT# 62 geographic atrophy 62 alveolar epithelial cells 62 follicular thyroid cancer 62 hyperoxaluria 62 transvaginal sonography 62 troponins 62 Metastatic breast cancer 62 para aortic 62 Solid Tumours 62 intraoperative complications 62 monoclonal gammopathy 62 breast tumors 62 varices 62 PIK3CA 62 colorectal neoplasia 62 pleurodesis 62 serum concentrations 62 rebleeding 62 retinal ischemia 62 hepatic lesions 62 prostate epithelial cells 62 multiple myeloma MM 62 malignant transformation 62 pancreatic prostate 62 Waldenstrom macroglobulinemia 62 LVNC 62 HbF 62 adrenal masses 62 histologies 62 Wilms tumors 62 ascites 62 heterozygotes 62 ERCC1 62 amyloid deposition 62 adnexal mass 62 BALB c mice 62 HER2 receptor 62 neoadjuvant treatment 62 HER2 ErbB2 62 EGFR HER2 62 deep venous thromboses 62 peripheral blood mononuclear 62 intestinal permeability 62 ischemic lesions 62 squamous 62 intraductal 62 tumor necrosis 62 colorectal adenomas 62 T2DM 62 FLT3 ITD 62 grade squamous intraepithelial 62 castrate resistant prostate cancer 62 #q#.# [001] 62 lymphoid malignancies 62 vWF 62 PARP inhibition 62 androgen independent 62 p# biomarker 62 cisplatin chemotherapy 62 carotid IMT 62 polycythemia vera PV 62 miRNA expression 62 oncologic outcomes 62 undetectable HBV DNA 62 gastrectomy 62 thyroid peroxidase 62 Severe Primary IGFD 62 benign noncancerous 62 polycythemia vera essential thrombocythemia 62 neurological manifestations 62 axilla 62 erythropoietic 62 etiologic 62 varicocele 62 Legg Calvé Perthes disease 62 multivariate logistic regression 62 recurrent miscarriage 62 MCF7 62 postoperative complication 62 cancer mCRC 62 uterine cancers 62 urethral stricture 62 papillary RCC 62 urothelium 62 lymphoid 62 refractory prostate cancer 62 neutropenic patients 62 LPS induced 62 Hashimoto thyroiditis 62 lesional 62 CTEPH 62 metastatic prostate cancer 62 pegylated liposomal doxorubicin 62 5FU 62 endoscopic ultrasonography 62 transplantation HCT 62 intravesical therapy 62 nonproliferative 62 prognostic indicators 62 MAPK pathway 62 hematologic toxicity 62 bleomycin 62 E cadherin expression 62 gene polymorphisms 62 BRAF mutations 62 MTHFR 62 malignant polyps 62 antiandrogen 62 Hematologic 62 Immunohistochemistry 62 tuberous sclerosis TS 62 cytogenetic abnormalities 62 chest radiography 62 plasma uric acid 62 hilar 62 lymphoma subtypes 62 rs# [002] 62 histopathologic diagnosis 62 glomerular filtration 62 myeloproliferative disorder 62 basal cell skin 62 essential thrombocythemia 62 IL#B 62 antitumor effect 62 hyperplastic polyps 62 HSCT 62 castration resistant prostate cancer 62 breast cancer metastasis 62 immunoblotting 62 promoter hypermethylation 62 de novo AML 62 metastatic ovarian cancer 62 TRUS biopsy 62 multivariate Cox 62 parathyroid 62 CD# + [001] 62 lymphoid cells 62 Natalizumab 62 hormone refractory 62 membranous nephropathy 62 polycystic kidneys 62 mycophenolate mofetil 62 TRAIL R1 62 mosaicism 62 catheter angiography 62 osteochondroma 62 TNFalpha 62 onset diabetes mellitus 62 susceptibility loci 62 serum creatinine levels 62 squamous carcinoma 62 Inhibin B 62 CHEK2 62 hypermethylation 62 Cholangiocarcinoma 62 postoperative morbidity 62 hypoperfusion 62 Toxicities 62 cardiac dysfunction 62 DNA methylation patterns 62 rheumatoid factor 62 adjuvant radiation 62 postoperative chemotherapy 62 BCR ABL mutations 62 PDGFR 62 murine models 62 hepatic metastasis 62 hypothalamic pituitary 62 intraepithelial neoplasia 62 intracranial hemorrhage ICH 62 carotid artery thickness 62 inhibin B 62 alkylating agents 62 resected 62 gastrointestinal stromal tumors 62 tumor biopsies 62 femoral neck fracture 62 lung adenocarcinoma 62 somatostatin receptors 62 heavily pretreated 62 Sentinel node biopsy 62 benign nodules 62 Sezary syndrome 62 hirsutism 62 thyroid carcinomas 62 MGd 62 esophageal squamous cell carcinoma 62 nodular 62 circulating endothelial cells 62 EGFR tyrosine kinase inhibitors 62 recurrent VTE 62 grade glioma 62 complement inhibitor eculizumab 62 Wilms tumor 62 parathyroid carcinoma 62 Prostatic 62 uterine tumors 62 gene rearrangements 62 HCV replicon 62 MSH2 62 CYT# potent vascular disrupting 61 STRIDE PD 61 chemoembolization 61 visceral metastases 61 thyroid nodule 61 activin 61 JMML 61 myelofibrosis polycythemia vera 61 β blockers 61 intravenous bisphosphonates 61 Factor Receptor 61 pseudotumor 61 fibromatosis 61 neuroendocrine cancers 61 CagA 61 vimentin 61 Surgical resection 61 Cell Lymphoma 61 pleural mesothelioma 61 gastric cancers 61 TURBT 61 MDR1 61 axillary node dissection 61 C#Y 61 lymphoproliferative 61 Enzastaurin 61 smoldering myeloma 61 hA# 61 Endometrial cancer 61 neovascularisation 61 seminal vesicle 61 latent celiac disease 61 hypomethylation 61 Medullary thyroid cancer 61 LV dysfunction 61 BCG refractory 61 mutated KRAS gene 61 Duodenal 61 pancreatic ductal adenocarcinoma 61 intratumoral 61 motor neuron degeneration 61 variant allele 61 proctitis 61 penetrance